

32. The method of claim **29**, **30** or **31**, wherein the first and second targeting portions are antibodies or fragments thereof, or ligands for the target molecules.

33. The method of any one of claims **29-32**, wherein the first and second target molecules are antigens or receptors.

34. Use of a binding protein as defined in any one of claims **1-20** in switching on a biological effect.

35. A method of switching on a biological effect, comprising:

- (1) administering two targeting molecules, wherein:
 - the first targeting molecule comprises a first targeting portion which binds specifically to a first target molecule on the target cell and wherein the targeting portion is linked to the first protein component of a transient protein:protein interaction; and

- the second targeting molecule comprises a second targeting portion which binds specifically to a second target molecule on the target cell and wherein the targeting portion is linked to the second protein component of the transient protein:protein interaction; and

- (2) administering a binding protein specific for a junctional epitope created by the transient protein:protein interaction, wherein the binding protein is as defined in any one of claims **1-20** and wherein administration of the binding protein switches on the biological effect.

36. A method of altering of a biological effect, comprising:

- (1) administering two targeting molecules, wherein:
 - the first targeting molecule comprises a first targeting portion which binds specifically to a first target molecule on the target cell and wherein the targeting portion is linked to the first protein component of a transient protein:protein interaction; and

- the second targeting molecule comprises a second targeting portion which binds specifically to a second target molecule on the target cell and wherein the targeting portion is linked to the second protein component of the transient protein:protein interaction; and

- (2) administering a binding protein specific for a junctional epitope created by the transient protein:protein interaction, wherein the binding protein is as defined in any one of claims **1-20** and wherein administration of the binding protein alters the biological effect.

37. The method of claim **35** or **36**, wherein the first and second targeting portions are antibodies or fragments thereof, or ligands for the target molecules.

38. The method of any one of claims **35-37**, wherein the first and second target molecules are antigens or receptors.

39. Use of a binding protein as defined in any one of claims **1-20** in cross-linking target cells.

40. A method of cross-linking two target cells using a binding protein, wherein the first target cell expresses a first target molecule and the second target cell expresses a second target molecule, and wherein the method comprises:

- (1) administering two targeting molecules, wherein:
 - the first targeting molecule comprises a first targeting portion which binds specifically to the first target molecule on the first target cell and wherein the targeting portion is linked to the first protein component of a transient protein:protein interaction; and
 - the second targeting molecule comprises a second targeting portion which binds specifically to the

- second target molecule on the second target cell and wherein the targeting portion is linked to the second protein component of the transient protein:protein interaction; and

- (2) administering a binding protein specific for a junctional epitope created by the transient protein:protein interaction, wherein the binding protein is as defined in any one of claims **1-20**.

41. A method of cross-linking two target cells, wherein the first target cell expresses a first and second target molecule and the second target cell expresses a third target molecule, and wherein the method comprises:

- (1) administering two targeting molecules, wherein:
 - the first targeting molecule comprises a first targeting portion which binds specifically to the first target molecule on the first target cell and wherein the targeting portion is linked to the first protein component of a transient protein:protein interaction; and
 - the second targeting molecule comprises a second targeting portion which binds specifically to the second target molecule on the first target cell and wherein the targeting portion is linked to the second protein component of the transient protein:protein interaction; and

- (2) administering a third targeting molecule comprising a third targeting portion which binds specifically to the third target molecule on the second target cell, wherein the targeting portion is linked to a binding protein specific for a junctional epitope created by the transient protein:protein interaction and wherein the binding protein is as defined in any one of claims **1-20**.

42. A method of cross-linking two target cells, wherein the first target cell expresses a first and second target molecule and wherein the second target cell is engineered to present a binding protein on its surface, and wherein the method comprises administering two targeting molecules, where:

- the first targeting molecule comprises a first targeting portion which binds specifically to the first target molecule on the first target cell and wherein the targeting portion is linked to the first protein component of a transient protein:protein interaction; and

- the second targeting molecule comprises a second targeting portion which binds specifically to the second target molecule on the first target cell and wherein the targeting portion is linked to the second protein component of the transient protein:protein interaction;

wherein the binding protein is as defined in any one of claims **1-20** above.

43. The method of claim **42**, wherein the second target cell is engineered to express the binding protein as a cell membrane fusion protein.

44. The method of any one of claims **40-43**, wherein:

- (a) the first, second and/or third, if present, targeting portions are antibodies or fragments thereof, or ligands for the target molecules; and/or
- (b) the first, second and/or third, if present, target molecules are antigens or receptors.

45. The method of any one of claims **40-44**, wherein the first or second target cell is an effector cell, such as a T cell.

46. The method of any one of claims **40-45**, wherein the first or second target cell is a cancer cell.

47. A method of treatment of the human or animal body, comprising administering a binding protein according to any one of claims **1-20**.